

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person*</b> <u>EVNIN ANTHONY B</u>  (Last) (First) (Middle)  C/O CONSTELLATION PHARMACEUTICALS, INC. 215 FIRST STREET, SUITE 200  (Street) CAMBRIDGE MA 02142  (City) (State) (Zip)	<b>2. Date of Event Requiring Statement (Month/Day/Year)</b> 07/18/2018	<b>3. Issuer Name and Ticker or Trading Symbol</b> <u>CONSTELLATION PHARMACEUTICALS INC [ CNST ]</u>	
		<b>4. Relationship of Reporting Person(s) to Issuer (Check all applicable)</b> <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	<b>5. If Amendment, Date of Original Filed (Month/Day/Year)</b>  <b>6. Individual or Joint/Group Filing (Check Applicable Line)</b> <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Preferred Stock	(1)	(1)	Common Stock	862,927	(1)	I	By funds <sup>(2)(3)(4)</sup>
Series B Preferred Stock	(5)	(5)	Common Stock	340,627	(5)	I	By funds <sup>(2)(3)(6)</sup>
Series D Preferred Stock	(7)	(7)	Common Stock	60,394	(7)	I	By funds <sup>(2)(3)(8)</sup>
Series E Preferred Stock	(9)	(9)	Common Stock	103,809	(9)	I	By funds <sup>(2)(3)(10)</sup>
Series E-1 Preferred Stock	(11)	(11)	Common Stock	109,786	(11)	I	By funds <sup>(2)(3)(12)</sup>
Series F Preferred Stock	(13)	(13)	Common Stock	908,359	(13)	I	By funds <sup>(2)(3)(14)</sup>
Warrant (right to buy)	(15)	05/24/2021	Common Stock	15,053	1.55	I	By funds <sup>(2)(3)(16)</sup>

**Explanation of Responses:**

- The Series A Preferred Stock is convertible into Common Stock on a 11.009-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
- Venrock Management V, LLC ("VM5"), Venrock Partners Management V, LLC ("VPM5"), and VEF Management V, LLC ("VEFM5") are the sole general partners of Venrock Associates V, L.P., Venrock Partners V, L.P. and Venrock Entrepreneurs Fund V, L.P. (collectively with Venrock Associates V and Venrock Partners V, the "Venrock Funds"), respectively, and may be deemed to own the shares held by the Venrock Funds. VM5, VPM5 and VEFM5 disclaim beneficial ownership of all the shares held by the Venrock Funds except to the extent of their proportionate pecuniary interest therein. Dr. Evnin is a member of VM5, VPM5 and VEFM5 and may be deemed to own the shares held by the Venrock Funds.
- (Continued from Footnote 2) Dr. Evnin disclaims beneficial ownership of all the shares held by the Venrock Funds, except to the extent of his indirect pecuniary interest therein. VHCP Management II, LLC ("VHCPM"), is the sole general partner and the sole manager of Venrock Healthcare Capital Partners II, L.P. and VHCP Co-Investment Holdings II, LLC (collectively with Venrock Healthcare Capital Partners II, the "VHCP II Funds"), respectively, and may be deemed to own the shares held by the VHCP II Funds. Dr. Evnin disclaims beneficial ownership of all the shares held by the VHCP II Funds except to the extent of his proportionate pecuniary interest therein.
- Consists of an aggregate of 778,621 shares of Common Stock issuable upon the conversion of shares of Series A Preferred Stock ("Series A Stock") held by Venrock Associates V, 18,293 shares of Common Stock issuable upon the conversion of shares of Series A Stock held by Venrock Entrepreneurs Fund V, and 66,013 shares of Common Stock issuable upon the conversion of shares of Series A Stock held by Venrock Partners V.
- The Series B Preferred Stock is convertible into Common Stock on a 11.009-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
- Consists of an aggregate of 307,350 shares of Common Stock issuable upon the conversion of shares of Series B Preferred Stock ("Series B Stock") held by Venrock Associates V, 7,220 shares of Common Stock issuable upon the conversion of shares of Series B Stock held by Venrock Entrepreneurs Fund V, and 26,057 shares of Common Stock issuable upon the conversion of shares of Series B Stock held by Venrock Partners V.
- The Series D Preferred Stock is convertible into Common Stock on a 11.009-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

8. Consists of an aggregate of 54,494 shares of Common Stock issuable upon the conversion of shares of Series D Preferred Stock ("Series D Stock") held by Venrock Associates V, 1,280 shares of Common Stock issuable upon the conversion of shares of Series D Stock held by Venrock Entrepreneurs Fund V, and 4,620 shares of Common Stock issuable upon the conversion of shares of Series D Stock held by Venrock Partners V.
9. The Series E Preferred Stock is convertible into Common Stock on a 8.56256-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
10. Consists of an aggregate of 93,668 shares of Common Stock issuable upon the conversion of shares of Series E Preferred Stock ("Series E Stock") held by Venrock Associates V, 2,200 shares of Common Stock issuable upon the conversion of shares of Series E Stock held by Venrock Entrepreneurs Fund V, and 7,941 shares of Common Stock issuable upon the conversion of shares of Series E Stock held by Venrock Partners V.
11. The Series E-1 Preferred Stock is convertible into Common Stock on a 11.009-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
12. Consists of an aggregate of 99,062 shares of Common Stock issuable upon the conversion of shares of Series E-1 Preferred Stock ("Series E-1 Stock") held by Venrock Associates V, 2,326 shares of Common Stock issuable upon the conversion of shares of Series E-1 Stock held by Venrock Entrepreneurs Fund V, and 8,398 shares of Common Stock issuable upon the conversion of shares of Series E-1 Stock held by Venrock Partners V.
13. The Series F Preferred Stock is convertible into Common Stock on a 11.009-for-one basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
14. Consists of an aggregate of 163,925 shares of Common Stock issuable upon the conversion of shares of Series F Preferred Stock ("Series F Stock") held by Venrock Associates V, 3,856 shares of Common Stock issuable upon the conversion of shares of Series F Stock held by Venrock Entrepreneurs Fund V, 13,901 shares of Common Stock issuable upon the conversion of shares of Series F Stock held by Venrock Partners V, 517,031 shares of Common Stock issuable upon the conversion of shares of Series F Stock held by Venrock Healthcare Capital Partners II and 209,646 shares of Common Stock issuable upon the conversion of shares of Series F Stock held by VHCP Co-Investment Holdings II.
15. The warrant is fully exercisable.
16. Consists of an aggregate of 13,583 warrants to purchase Common Stock held by Venrock Associates V, 1,151 warrants to purchase Common Stock held by Venrock Partners V, and 319 warrants to purchase Common Stock held by Venrock Entrepreneurs Fund V.

**Remarks:**

Exhibit Index: 24.1 Power of Attorney

/s/ Emma Reeve, as attorney-  
in-fact for Anthony B. Evnin      07/18/2018

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

LIMITED POWER OF ATTORNEY  
FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Jigar Raythatha, Emma Reeve and Karen Valentine, signing singly and each acting individually, as the undersigned's true and lawful attorney-in-fact with full power and authority as hereinafter described to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer of Constellation Pharmaceuticals, Inc. (the "Company"), Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder (the "Exchange Act");

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form with the United States Securities and Exchange Commission (the "SEC") and any stock exchange or similar authority, including without limitation the filing of a Form ID, Update Passphrase, or any other application materials to enable the undersigned to gain or maintain access to the Electronic Data Gathering, Analysis and Retrieval system of the SEC;

(3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to such attorney-in-fact and approves and ratifies any such release of information; and

(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. The undersigned acknowledges that neither the Company nor the foregoing attorneys-in-fact assume (i) any liability for the undersigned's responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 2nd day of July, 2018.

/s/ Anthony Evnin

-----  
Name: Anthony Evnin